AU2020394993A1 - Ny-eso-1-containing artificial adjuvant vector cell for use in treatment of cancer - Google Patents

Ny-eso-1-containing artificial adjuvant vector cell for use in treatment of cancer Download PDF

Info

Publication number
AU2020394993A1
AU2020394993A1 AU2020394993A AU2020394993A AU2020394993A1 AU 2020394993 A1 AU2020394993 A1 AU 2020394993A1 AU 2020394993 A AU2020394993 A AU 2020394993A AU 2020394993 A AU2020394993 A AU 2020394993A AU 2020394993 A1 AU2020394993 A1 AU 2020394993A1
Authority
AU
Australia
Prior art keywords
eso
cell
aavc
fragment
cd1d
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020394993A
Other languages
English (en)
Inventor
Ayaka Akiba
Shinichiro Fujii
Yasuhide Masuhara
Keisuke Ohsumi
Tatsuya Okudaira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
RIKEN
Original Assignee
Astellas Pharma Inc
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, RIKEN filed Critical Astellas Pharma Inc
Publication of AU2020394993A1 publication Critical patent/AU2020394993A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2020394993A 2019-12-02 2020-12-01 Ny-eso-1-containing artificial adjuvant vector cell for use in treatment of cancer Abandoned AU2020394993A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019217704 2019-12-02
JP2019-217704 2019-12-02
PCT/JP2020/044586 WO2021112055A1 (ja) 2019-12-02 2020-12-01 がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞

Publications (1)

Publication Number Publication Date
AU2020394993A1 true AU2020394993A1 (en) 2022-06-09

Family

ID=76222293

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020394993A Abandoned AU2020394993A1 (en) 2019-12-02 2020-12-01 Ny-eso-1-containing artificial adjuvant vector cell for use in treatment of cancer

Country Status (21)

Country Link
US (2) US11672851B2 (https=)
EP (1) EP4071240A4 (https=)
JP (1) JP7646213B2 (https=)
KR (1) KR20220119030A (https=)
CN (1) CN114787344A (https=)
AR (1) AR120648A1 (https=)
AU (1) AU2020394993A1 (https=)
BR (1) BR112022010763A2 (https=)
CA (1) CA3162277A1 (https=)
CL (1) CL2022001459A1 (https=)
CO (1) CO2022008738A2 (https=)
CR (1) CR20220320A (https=)
DO (1) DOP2022000108A (https=)
EC (1) ECSP22049399A (https=)
IL (1) IL293482A (https=)
JO (1) JOP20220121A1 (https=)
MX (1) MX2022006716A (https=)
PE (1) PE20221463A1 (https=)
PH (1) PH12022551334A1 (https=)
TW (1) TW202134431A (https=)
WO (1) WO2021112055A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
WO2025230010A1 (ja) * 2024-05-02 2025-11-06 国立研究開発法人理化学研究所 ＣＤ１ｄ導入前にＣＤ１ｄリガンドでインキュベートされた細胞

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5672647B2 (ja) * 2006-02-22 2015-02-18 独立行政法人理化学研究所 ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
JP2007261876A (ja) 2006-03-28 2007-10-11 Tdk Corp 誘電体粒子、誘電体磁器組成物およびその製造方法
WO2008057795A2 (en) * 2006-10-27 2008-05-15 Temple University - Of The Commonwealth System Of Higher Education Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera
AU2008219020B2 (en) * 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
JPWO2010061930A1 (ja) * 2008-11-28 2012-04-26 独立行政法人理化学研究所 ＣＤ１ｄ及び標的抗原の共発現アロ細胞を用いた免疫療法
KR101194265B1 (ko) 2008-12-01 2012-10-29 주식회사 한국인삼공사 해양심층수를 이용하여 인삼 또는 홍삼 농축액의 고미 제거방법
BR112012024375A2 (pt) 2010-03-25 2016-05-24 3M Innovative Properties Co camada compósita
EP2738253A4 (en) 2011-07-29 2015-04-22 Riken CELL FOR USE IN IMMUNOTHERAPY WITH A MODIFIED NUCLEIC ACIDIC CONSTRUCTIVE FOR WILMS TUMORGEN PRODUCT OR FRAGMENT THEREOF, METHOD FOR PRODUCING THIS CELL AND NUCLEIC ACIDIC CONCRETE SAID
US10316332B2 (en) * 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
CN108064176A (zh) * 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
EP3328988A1 (en) 2015-07-31 2018-06-06 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
JP2020514370A (ja) * 2017-03-17 2020-05-21 キュアバック アーゲー 組合せ抗癌療法のためのｒｎａワクチン及び免疫チェックポイント阻害剤

Also Published As

Publication number Publication date
US11672851B2 (en) 2023-06-13
JOP20220121A1 (ar) 2022-05-23
CL2022001459A1 (es) 2023-02-24
MX2022006716A (es) 2022-09-12
EP4071240A4 (en) 2024-01-17
KR20220119030A (ko) 2022-08-26
DOP2022000108A (es) 2022-10-31
US20230330200A1 (en) 2023-10-19
WO2021112055A1 (ja) 2021-06-10
AR120648A1 (es) 2022-03-09
CA3162277A1 (en) 2021-06-10
JPWO2021112055A1 (https=) 2021-06-10
EP4071240A1 (en) 2022-10-12
US20230000965A1 (en) 2023-01-05
TW202134431A (zh) 2021-09-16
BR112022010763A2 (pt) 2022-08-23
JP7646213B2 (ja) 2025-03-17
CN114787344A (zh) 2022-07-22
ECSP22049399A (es) 2022-08-31
PE20221463A1 (es) 2022-09-21
IL293482A (en) 2022-08-01
PH12022551334A1 (en) 2023-11-20
CO2022008738A2 (es) 2022-07-19
CR20220320A (es) 2022-11-03

Similar Documents

Publication Publication Date Title
US6635624B1 (en) Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis
KR102533540B1 (ko) Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거(elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells)
CN110511960A (zh) 抗人乳头瘤病毒16 e6 t细胞受体
CN112980886B (zh) 一种能高效制备且应用安全的嵌合抗原受体t细胞及其制备方法与应用
KR20100040740A (ko) 신규 ａｓ160 유사 단백질, 이를 포함하는 제2형 당뇨병 치료제 동정을 위한 시험 시스템, 방법 및 용도
CN117545765A (zh) 嵌合抗原受体t细胞
CN100548385C (zh) 一种布鲁氏杆菌核酸疫苗
AU2020394993A1 (en) Ny-eso-1-containing artificial adjuvant vector cell for use in treatment of cancer
KR20080033271A (ko) 암종을 위한 다가 동반이행 및 증폭형 면역치료제
CN110559430B (zh) 一种抗淋巴瘤的car-t药物及其应用
JP2023051923A (ja) 腫瘍標的化型ビーズベクターおよびその使用方法
US6429201B1 (en) Method for immunization against hepatitis B
HK40068363A (en) Ny-eso-1-containing artificial adjuvant vector cell used for treating cancer
CN110628823B (zh) 一种cd30 car慢病毒表达载体及其制备方法和应用
KR102912340B1 (ko) 헌팅턴병의 치료 및/또는 예방을 위한 아실-단백질 티오에스테라제 억제제
CN117751181A (zh) 嵌合抗原受体t细胞
CN114350657B (zh) 一种促进环状rna生成的反向互补短侧翼序列及其应用
KR101732126B1 (ko) 췌장암 치료용 융합 단백질 및 이의 용도
KR20180030358A (ko) 재조합 간암세포주를 이용하여 다양한 레벨의 miR-122 발현을 조절하는 방법
KR20190049456A (ko) 내인성 폴리펩타이드 생산을 위한 재조합 세포 및 방법
CN117769566A (zh) 嵌合抗原受体t细胞
HK40016948B (en) Anti-human papillomavirus 16 e6 t cell receptors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ NY-ESO-1-CONTAINING ARTIFICIAL ADJUVANT VECTOR CELL FOR USE IN TREATMENT OF CANCER

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period